Company Overview of Cylene Pharmaceuticals, Inc.
Cylene Pharmaceuticals, Inc., a biotech pharmaceutical company, engages in the discovery and development of small molecule drugs for the treatment of cancer deceases. The company’s products include oral inhibitors of the cancer-linked serine/threonine protein kinases (CK2 and Pim); and oral agents that activate p53 via modulation of RNA Polymerase I activity in the upstream ribosome biogenesis pathway. Cylene Pharmaceuticals, Inc. was formerly known as Cyternex, Inc. and changed its name in October 2003. The company was founded in 1997 and is based in San Diego, California.
5820 Nancy Ridge Drive
San Diego, CA 92121
Founded in 1997
Key Executives for Cylene Pharmaceuticals, Inc.
Senior Vice President of Clinical & Regulatory Affairs
Senior Vice President of Chemistry & Pharmaceutical Operations
Vice President of Research & Business Development
Compensation as of Fiscal Year 2014.
Cylene Pharmaceuticals, Inc. Key Developments
Cylene Pharmaceuticals, Inc. and TetraGene LLC Enter Agreement for Quarfloxin and Anticancer Quadruplex Technologies
Mar 6 13
Cylene Pharmaceuticals, Inc. announced that it has entered into an exclusive, worldwide Option and License Agreement that will allow TetraGene LLC to advance the development of Quarfloxin and Cylene's associated anticancer quadruplex-targeting technologies. Cylene will receive an upfront fee, as well as potential milestone payments and royalties on product sales for the exclusive license. TetraGene is developing small molecule drugs aimed at highly validated cancer-causing genes, by directly targeting G-quadruplex structures in genomic DNA. TetraGene has the option to acquire worldwide rights to the technologies licensed from Cylene, which include the Phase II compound Quarfloxin and several registered patents. Quarfloxin has been demonstrated to be safe and well-tolerated in Phase I clinical trials. Cylene Pharmaceuticals is a clinical-stage private company developing small molecule drugs against newly validated targets in essential cancer pathways. The company's Pol I program provides a non-genotoxic mechanism for activating p53 to kill cancer cells. Cylene's leadership in exploiting CK2 pathways enables rational drug combinations for improved treatment outcomes against many cancer indications. Cylene's unique approaches deliver innovative cancer agents that can enable pharmaceutical companies to expand their portfolios and extend the efficacy, lifecycle and reach of current cancer therapeutics.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries